DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

LaunchTrends: Perjeta and Kadcyla (Breast Cancer) (Wave 3) US 2013

BioTrends Research Group announces a new syndicated report series, LaunchTrends®: Perjeta (pertuzumab) & Kadcyla (Trastuzumab DM-1 (T-DM1). This four-wave primary research study will follow the United States launch of Roche/Genentech/Chugai’s Perjeta at around one (Wave 1), six (Wave 2), twelve (Wave 3) and twenty-one (Wave 4) months after product availability and Kadcyla at around six (Wave 3) and twelve months (Wave 4) post availability.
LaunchTrends® are syndicated reports that track the trial, adoption, and usage of new products from launch through maturity. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and change treatment dynamics. They provide information on physician awareness, familiarity, and perceived clinical advantages and disadvantages of new products. In addition, they capture the promotional messages and activities of the marketing company.

Questions Answered in This Report:

  • Understand awareness of and familiarity with Perjeta & Kadcyla among Medical Oncologists

  • Understand the perceived clinical advantages and disadvantages of Perjeta & Kadcyla compared to other marketed agents used in treating HER2-positive breast cancer

  • Understand where Perjeta & Kadcyla is expected to fit in the treatment algorithm for patients with HER2-positive breast cancer

  • Track the trial, adoption, and usage trends including anticipated future trends for the treatment of HER2-positve breast cancer

  • Collect information on the promotional messages and activities being employed by Genentech / Roche

  • Capture interest and anticipated value of next generation therapies in development


Sample Frame & Methodology:

- This report will include responses from a random sample of 75 Medical Oncologists

- A qualitative follow up arm includes telephone interviews conducted with a sub-set of 15 survey respondents

To qualify for participation, Medical Oncologists must meet the following criteria: :

- In practice between 2 and 30 years

- Minimum of 20 patients with breast cancer personally treated over the last year

- More than 75% of time spent in clinical practice


- Final report in powerpoint format (from each wave)

- Complete set of frequency tables, summary statistics, and cross tabulations

- Copies of telephone interviews (as audio files; blinded)

- Proprietary question slide deck and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Product Coverage:

- Herceptin, Tykerb, Perjeta, Kadcyla and combination regimens

Companion Reports - BioTrends:

- TreatmentTrends®: Metastatic Breast Cancer (US)

- TreatmentTrends®: Metastatic Breast Cancer (EU)

Companion Reports - Decision Resources:

- Pharmacor Breast Cancer

- Breast Cancer in the BRIC Markets

- Breast Cancer Patient Flow